Reimagining Pharmacy for Life-Altering Gene Therapies

The pharmaceutical industry is shifting to precision medicine, particularly in gene therapy, necessitating advanced logistics and infrastructure for efficient delivery, with significant market growth expected.

Life Sciences Review | Thursday, March 05, 2026

The global pharmaceutical landscape is moving from a "one-size-fits-all" model of small-molecule drugs to the era of precision medicine. At the forefront of this transformation is the gene therapy sector, a field that has matured from experimental science into a commercially viable therapeutic category. As these advanced therapy medicinal products (ATMPs) move from clinical trials to commercialization, they necessitate a complete reimagining of pharmacy operations. The market for gene therapy pharmacy solutions—encompassing specialized logistics, handling, data management, and financial modeling—is poised for exponential growth, driven by an urgent need to support the safe and efficient delivery of these life-altering treatments.

Economic Trajectory and Market Expansion

The economic indicators for the gene therapy sector indicate the market is entering a phase of rapid acceleration. Projections for the coming decade suggest that the global gene therapy market will expand at a CAGR exceeding 20 percent, potentially surpassing a $50 billion valuation by the mid-2030s. This robust growth is fueled not only by technological breakthroughs in viral vector engineering and gene editing tools like CRISPR but also by a fundamental shift in regulatory attitudes. Regulatory bodies worldwide are increasingly adopting expedited pathways, recognizing the potential of these therapies to address previously untreatable genetic disorders and complex oncological conditions.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

This market expansion is catalyzing a parallel boom in the "pharmacy solutions" sector. As the pipeline of approved therapies grows, so does the demand for a commercial infrastructure capable of supporting them. Unlike traditional pharmaceuticals, which rely on volume-based distribution, gene therapies operate on high-value, low-volume models that require precision at every step. This economic reality is driving significant capital into the development of specialized commercialization services. Stakeholders are witnessing a surge in value for services that can navigate the complex reimbursement landscape, where innovative payment models—such as annuity-based payments or outcomes-based rebates—are replacing traditional transaction structures. Consequently, the financial plumbing of the pharmacy industry is being overhauled to accommodate therapies with seven-figure price tags, creating a lucrative niche for financial technology solutions tailored to healthcare.

Next-Generation Pharmacy Operations and Infrastructure

The operational reality of handling gene therapies demands a radical departure from standard pharmacy practices. The "pharmacy of the future" for gene therapy is not merely a dispensing unit but a sophisticated biotech hub involving intricate chain-of-identity (COI) and chain-of-custody (COC) protocols. Because many of these therapies are autologous—derived from a patient’s own cells—the pharmacy solution must ensure zero margin for error in tracking biological material from collection to manufacturing and back to infusion.

Infrastructure requirements are shifting towards ultra-cold chain capabilities. Pharmacies within Centers of Excellence and specialized treatment hubs are retrofitting facilities to house liquid nitrogen freezers and cryo-preservation units, maintaining temperatures as low as -196°C. Beyond storage, the actual preparation of these doses requires advanced aseptic handling procedures.

The operational workflow is becoming increasingly digitized. Pharmacy information systems are evolving to integrate directly with manufacturer portals and hospital electronic health records (EHRs). This interoperability is critical for real-time monitoring of product integrity during transit and storage. The industry is moving toward "smart pharmacy" models where Internet of Things (IoT) sensors continuously monitor environmental conditions, automatically flagging any temperature excursions that could compromise the efficacy of these fragile biological products. This operational complexity elevates the role of the pharmacist to that of a clinical logistics manager, overseeing a highly choreographed process that blends clinical care with advanced supply chain management.

Strategic Investment Frontiers

Investors entering the gene therapy pharmacy solutions market will find a broad array of high-value opportunities, particularly in the foundational technologies and services that enable the sector’s operational growth. These “picks and shovels” represent some of the most accessible and scalable investment avenues as the field transitions from early development to commercial maturity.

A prominent area of focus is specialized logistics and cold-chain management. Demand is accelerating for third-party logistics providers with dedicated expertise in cryogenic and tightly controlled temperature transport. As gene therapies advance from clinical deployment to broader commercial use, the market faces a growing need for premium, precision-driven courier services that ensure temperature stability, regulatory compliance, and time-critical delivery. This gap between supply and demand presents a meaningful window for investment.

Data analytics and software infrastructure are also rapidly expanding segments. The long-term tracking required for outcomes-based reimbursement has created strong demand for platforms that can securely integrate data among payers, providers, and manufacturers. Investors are increasingly supporting solutions that manage multi-year patient outcomes, ensure data integrity, and facilitate evidence generation on therapy durability—capabilities that are becoming essential as payment models evolve.

Contract Development and Manufacturing Organizations are expanding their scope beyond production to integrate more closely with pharmacy delivery channels. CDMOs offering comprehensive end-to-end, or “vein-to-vein,” services—from vector manufacturing to fill-finish operations and pharmacy kit preparation—are emerging as desirable targets. Their ability to streamline the transition between manufacturing and clinical pharmacy operations is a significant differentiator in a complex supply chain.

Regulatory and compliance consulting is forming a high-demand niche as accreditation requirements for handling advanced therapy medicinal products (ATMPs) continue to intensify. Consulting firms that provide readiness assessments, staff training, and compliance support for hospital pharmacies and specialty hubs are gaining traction. These service lines require relatively modest capital to establish yet address critical operational needs, making them compelling investment opportunities within the broader gene therapy ecosystem.

The growth of gene therapy pharmacy solutions is a structural evolution of the healthcare supply chain. It represents a move away from commoditized drug dispensing toward a highly specialized, technology-driven service model. For the industry, the path forward involves deep integration of clinical expertise with advanced logistics and data science. For investors, it presents a frontier where capital deployment can support the infrastructure necessary to deliver the next generation of medical miracles to patients worldwide.

More in News

Pharmaceutical Compliance in a Serialized Supply Chain

Pharmaceutical compliance has moved beyond recordkeeping into the daily movement of product, data and accountability across the supply chain. For manufacturers, wholesale distributors and third-party logistics providers, compliance now depends on whether each package can be identified, verified, traced and reported without forcing teams to reconcile disconnected systems. The pressure is not only regulatory. Counterfeit risk, expired product control, trading partner accuracy and audit readiness all sit inside the same business workflow. A strong compliance platform must bring those demands together without turning compliance into a parallel process that slows commercial activity or leaves leaders dependent on fragmented reports. The most reliable solutions are built around traceability at the transaction level. Serialization cannot be treated as a late-stage attachment to inventory management because the value of a serial number depends on how consistently it travels through purchasing, receiving, sales, returns, financial records and partner exchange. When serialization lives outside the system that manages the business, companies often inherit duplicate entries, timing gaps and inconsistent product data. Those weaknesses become expensive when regulators require proof, customers request verification or leadership needs a clean view of inventory exposure. A better system keeps compliance evidence close to the events that create it, allowing teams to act from the same source of truth rather than comparing data after problems appear. Executives should also look closely at how a platform handles reporting and exception management. Pharma teams need systems that can capture required data, generate reports and support Drug Supply Chain Security Act obligations without relying on manual workarounds. The right solution should reduce dependence on extra staffing for routine tasks, give teams timely visibility into product status and help prevent expired or suspect products from moving forward. Compliance technology should not simply store information. It should make the right information available when a trading partner, regulator or internal leader needs it. That level of discipline becomes especially important for companies operating across multiple states, serving many customers or managing products whose lifecycle data must remain accurate from receipt to distribution. Data protection has become equally central because cloud-based compliance systems hold commercially sensitive information about product movement, customers, orders and financial activity. Encryption, network security, threat detection and compliance controls are no longer supporting features. They are part of the decision. Executives need confidence that the platform protects proprietary data while still enabling authorized users to work across sites, functions and partners. Scalability also matters because pharmaceutical companies rarely remain static. License expansion, new partner relationships, added states, higher transaction volume and broader service lines can quickly expose whether a system was designed for growth or merely configured for a current process. “ For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. “ This is where RxERP stands out as the premier choice for pharmaceutical organizations that need compliance embedded into core business execution rather than added around it. Its platform combines ERP functionality with automated serialization, traceability, reporting, inventory, finance, CRM and business intelligence for manufacturers, distributors and third-party logistics providers. The transcript points to a wholesaler and 3PL that replaced fragmented systems with one integrated platform, improving automation, reporting, data management and DSCSA compliance while achieving measurable financial and revenue gains. For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Specials

Reimagining Pharmacy for Life-Altering Gene Therapies

The pharmaceutical industry is shifting to precision medicine, particularly in gene therapy, necessitating advanced logistics and infrastructure for efficient delivery, with significant market growth expected.